Hepatology International

, Volume 2, Issue 2, pp 179–184 | Cite as

Should chronic HBV infected patients with normal ALT treated: debate

  • Shiv Kumar SarinEmail author
  • Manoj Kumar
Review article


Alanine aminotransferase (ALT) levels have traditionally been used for treatment decisions in chronic hepatitis B virus (CHBV) infected patients. But recent data have raised doubts on this wisdom, as a significant proportion of CHBV infected patients with normal ALT have high HBVDNA levels and significant liver injury at presentation especially in areas of intermediate to high endemicity. A normal ALT value only identifies patients less likely to respond to current treatments, rather than patients who are not in need of the treatment. Patients with CHBV infection with normal ALT should be considered for treatment based on the HBV DNA levels and histological injury.


Chronic Hepatitis B ALT 


  1. 1.
    de Franchis R, Hadengue A, Lau G, Lavanchy D, Lok A, McIntyre N, et al. EASL International Consensus Conference on Hepatitis B. 13–14 September, 2002 Geneva, Switzerland. Consensus statement (long version). J Hepatol. 2003;39(Suppl 1):S3–25.PubMedGoogle Scholar
  2. 2.
    Tsai SL, Chen PJ, Lai MY, Yang PM, Sung JL, Huang JH, et al. Acute exacerbations of chronic type B hepatitis are accompanied by increased T cell responses to hepatitis B core and e antigens: implications for hepatitis B e antigen seroconversion. J Clin Invest. 1992;89:87–96.PubMedCrossRefGoogle Scholar
  3. 3.
    Hsu YS, Chien RN, Yeh CT, Sheen IS, Chiou HY, Chu CM, et al. Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology. 2002;35:1522–7.PubMedCrossRefGoogle Scholar
  4. 4.
    Hadziyannis SJ, Vassilopoulos D. Hepatitis B e antigen-negative chronic hepatitis B. Hepatology. 2001;34:617–24.PubMedCrossRefGoogle Scholar
  5. 5.
    Brunetto MR, Oliveri F, Coco B, Leandro G, Colombatto P, Gorin JM, et al. Outcome of anti-HBe positive chronic hepatitis B in alpha–interferon treated and untreated patients: a long term cohort study. J Hepatol. 2002;36:263–70.PubMedCrossRefGoogle Scholar
  6. 6.
    Manno M, Camma C, Schepis F, Bassi F, Gelmini R, Giannini F, et al. Natural history of chronic HBV carriers in northern Italy: morbidity and mortality after 30 years. Gastroenterology. 2004;127:756–63.PubMedCrossRefGoogle Scholar
  7. 7.
    Chen YC, Sheen IS, Chu CM, Liaw YF. Prognosis following spontaneous HBsAg seroclearance in chronic hepatitis B patients with or without concurrent infection. Gastroenterology. 2002;123:1084–9.PubMedCrossRefGoogle Scholar
  8. 8.
    Lai CL, Ratziu V, Yuen MF, Poynard T. Viral hepatitis B. Lancet. 2003;362:2089–94.PubMedCrossRefGoogle Scholar
  9. 9.
    Chu CM, Hung SJ, Lin J, Tai DI, Liaw YF. Natural history of hepatitis B e antigen to antibody seroconversion in patients with normal serum aminotransferase levels. Am J Med. 2004;116:829–34.PubMedCrossRefGoogle Scholar
  10. 10.
    Yuen MF, Yuan HJ, Wong DK, Yuen JC, Wong WM, Chan AO, et al. Prognostic determinants for chronic hepatitis B in Asians: therapeutic implications. Gut. 2005;54:1610–4.PubMedCrossRefGoogle Scholar
  11. 11.
    Shafritz DA, Shouval D, Sherman HI, Hadziyannis SJ, Kew MC. Integration of hepatitis B virus DNA into the genome of liver cells in chronic liver disease and hepatocellular carcinoma. Studies in percutaneous liver biopsies and post-mortem tissue specimens. N Engl J Med. 1981;305:1067–73.PubMedCrossRefGoogle Scholar
  12. 12.
    Prati D, Taioli E, Zanella A, Della Torre E, Butelli S, Del Vecchio E, et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med. 2002;137:1–9.PubMedGoogle Scholar
  13. 13.
    Puoti C, Magrini A, Stati T, Rigato P, Montagnese F, Rossi P, et al. Clinical, histological, and virological features of hepatitis C virus carriers with persistently normal or abnormal alanine transaminase levels. Hepatology. 1997;26:1393–8.PubMedCrossRefGoogle Scholar
  14. 14.
    Piton A, Poynard T, Imbert-Bismut F, Khalil L, Delattre J, Pelissier E, et al. Factors associated with serum alanine transaminase activity in healthy patients: consequences for the definition of normal values, for selection of blood donors, and for patients with chronic hepatitis C. MULTIVIRC Group. Hepatology. 1998;27:1213–9.PubMedCrossRefGoogle Scholar
  15. 15.
    Kim HC, Nam CM, Jee SH, Han KH, Oh DK, Suh I. Normal serum aminotransferase concentration and risk of mortality from liver diseases: prospective cohort study. BMJ. 2004;328:983–8.PubMedCrossRefGoogle Scholar
  16. 16.
    Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ, et al. The risk evaluation of viral load elevation and associated liver disease/cancer. Gastroenterology. 2006;130:678–86.PubMedCrossRefGoogle Scholar
  17. 17.
    Ricci G, De Bac C, Caramia F. Carriers of hepatitis B antigen: an epidemiologic and histologic study. J Infect Dis. 1973;128:125–8.PubMedGoogle Scholar
  18. 18.
    Tapp E, Jones DM, Hollanders D, Dymock IW. Serial liver biopsies in blood donors with persistent HBs antigenaemia. J Clin Pathol. 1976;29:884–6.PubMedCrossRefGoogle Scholar
  19. 19.
    Dragosics B, Ferenci P, Hitchman E, Denk H. Long-term follow-up study of asymptomatic HBsAg-positive voluntary blood donors in Austria: a clinical and histologic evaluation of 242 cases. Hepatology. 1987;7:302–6.PubMedCrossRefGoogle Scholar
  20. 20.
    de Franchis R, D’Arminio A, Vecchi M, Ronchi G, Del Ninno E, Parravicini A, et al. Chronic asymptomatic HBsAg carriers: histologic abnormalities and diagnostic and prognostic value of serologic markers of the HBV. Gastroenterology. 1980;79:521–7.PubMedGoogle Scholar
  21. 21.
    Lin CL, Liao LY, Liu CJ, Yu MW, Chen PJ, Lai MY, et al. Hepatitis B viral factors in HBeAg-negative carriers with persistently normal serum alanine aminotransferase levels. Hepatology. 2007;45(5):1193–8.PubMedCrossRefGoogle Scholar
  22. 22.
    Li J, Zhao GM, Zhu LM, Li Y, Xin SJ. Liver pathological changes and clinical features of patients with chronic hepatitis B virus infection in their immune tolerant phase and non-active status. Zhonghua Gan Zang Bing Za Zhi. 2007;15(5):326–9.PubMedGoogle Scholar
  23. 23.
    Lai M, Hyatt BJ, Nasser I, Curry M, Afdhal NH. The clinical significance of persistently normal ALT in chronic hepatitis B infection. J Hepatol. 2007;47(6):760–7.PubMedCrossRefGoogle Scholar
  24. 24.
    Keeffe EB, Dieterich DT, Han SH, Jacobson RM, Martin P, Schiff ER, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update. Clin Gastroenterol Hepatol. 2006;4:936–62.PubMedCrossRefGoogle Scholar
  25. 25.
    Chen CJ, Yu MW, Liaw YF. Epidemiological characteristics and risk factors of hepatocellular carcinoma. J Gastroenterol Hepatol. 1997;12:S294–308.PubMedCrossRefGoogle Scholar
  26. 26.
    Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SM, et al. REVEAL-HBV Study Group. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA. 2006;295:65–73.PubMedCrossRefGoogle Scholar
  27. 27.
    Keeffe EB, Dieterich DT, Han SH, Jacobson IM, Martin P, Schiff ER, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States. Clin Gastroenterol Hepatol. 2004;2:87–106.PubMedCrossRefGoogle Scholar
  28. 28.
    Yuen MF, Yuan HJ, Wong DK, Yuen JC, Wong WM, Chan AO, et al. Prognostic determinants for chronic hepatitis B in Asians: therapeutic implications. Gut. 2005;54:1610–4.PubMedCrossRefGoogle Scholar
  29. 29.
    Mommeja-Marin H, Mondou E, Blum MR, Rousseau F. Serum HBV DNA as a marker of efficacy during therapy for chronic HBV infection: analysis and review of the literature. Hepatology. 2003;37:1309–19.PubMedCrossRefGoogle Scholar
  30. 30.
    Dienstag JL, Goldin RD, Heathcote EJ, Hann HW, Woessner M, Stephenson SL, et al. Histological outcome during long-term lamivudine therapy. Gastroenterology. 2003;124:105–17.PubMedCrossRefGoogle Scholar
  31. 31.
    Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N Engl J Med. 2005;352:2673–81.PubMedCrossRefGoogle Scholar
  32. 32.
    Lai CL, Shouval D, Lok AS, Chang TT, Cheinquer H, Goodman Z, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med. 2006;354:1011–20.PubMedCrossRefGoogle Scholar
  33. 33.
    Chang TT, Gish RG, de Man R, Gadano A, Sollano J, Chao YC, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med. 2006;354:1001–10.PubMedCrossRefGoogle Scholar
  34. 34.
    Liaw YF, Sung JJ, Chow WC, Farrel G, Lee CZ, Yuen H, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med. 2004;351:1521–31.PubMedCrossRefGoogle Scholar
  35. 35.
    Yuen MF, Seto WK, Chow DHF, Tsui K, Wong DKH, Chan P, et al. Long-term beneficial outcome of Chinese asymptomatic patients with HBeAg-positive chronic hepatitis B on continuous lamivudine therapy. Program and abstracts of the 57th Annual Meeting of the American Association for the Study of Liver Diseases; November 11–15, 2005; San Francisco, California. Abstract 985.Google Scholar
  36. 36.
    Averett DR, Mason WS. Evaluation of drugs for antiviral activity against hepatitis B virus. Viral Hepatitis Rev. 1995;1:129–42.Google Scholar
  37. 37.
    Yuen MF, Wong DKH, Sum SS, Yuan HJ, Yuen JC, Chan AO, et al. Effect of lamivudine therapy on the serum covalently closed-circular (ccc) DNA of chronic hepatitis B infection. Am J Gastroenterol. 2005;100:1099–103.PubMedCrossRefGoogle Scholar
  38. 38.
    Werle-Lapostolle B, Bowden S, Locarnini S, Wursthom K, Petersen J, Lav G, et al. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology. 2004;126:1750–8.PubMedCrossRefGoogle Scholar
  39. 39.
    Wong DKH, Yuen MF, Ngai VWS, Fung J, Lai CL. One-year entecavir or lamivudine therapy results in reduction of HBV intrahepatic covalently closed circular DNA levels. Antiviral Ther. 2006;11(7):909–16.Google Scholar
  40. 40.
    Wursthorn K, Lutgehetmann M, Dandri M, Volz T, Buggisch P, Zollner B, et al. Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B. Hepatology. 2006;44(3):675–84.PubMedCrossRefGoogle Scholar
  41. 41.
    Enriquez AD, Campbell MS, Reddy KR. Cost-effectiveness of suppressing hepatitis B virus DNA in immune tolerant patients to prevent hepatocellular carcinoma and cirrhosis. Aliment Pharmacol Ther. 2007;26(3):383–91.PubMedCrossRefGoogle Scholar

Copyright information

© Asian Pacific Association for the Study of the Liver 2008

Authors and Affiliations

  1. 1.Department of GastroenterologyG.B. Pant HospitalNew DelhiIndia

Personalised recommendations